Margaret Haugh (MediCom Consult) provided translation and editing services, which was funded by Sanofi Pasteur MSD. Box 1. Current nomenclature for influenza viruses (WHO 1980). The formal ...

Sanofi Vietnam has cooperated with the VinaCapital Foundation (VCF) since April 2024 to implement a heart disease screening and influenza vaccination programme for people in Quang Binh and Tra Vinh ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque ...

while VaxigripTetra is manufactured by Sanofi and locally distributed by Sanofi Aventis. Two other influenza vaccines that have been brought into Singapore for the Northern Hemisphere 2020/21 ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Agomab Ther­a­peu­tics is ben­e­fit­ing from Sanofi’s push to be­come an im­munol­o­gy pow­er­house.

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

Wide-moat Sanofi reported better-than-expected third-quarter earnings driven by strong performance of the RSV prophylaxis drug Beyfortus and influenza vaccines. We've increased our fair value ...

Aside from Beyfortus, Sanofi’s other vaccines also showed growth in Q3, including its meningitis and influenza shots. “Our strong growth in the quarter was accelerated by the outstanding performance ...

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...